Sex Transm Infect
CagriSema is a two-peptide amylin + GLP-1 combination
Oral use has occasionally been linked to nausea, and theoretical hypotension concerns exist due to nitric oxide pathway activity
AMERICAS GLUTATHIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION) TABLE 226
Hopfner et al., 2017), and increase in Akkermansia /Verrucomicrobiaceae (Keshavarzian et al., 2015
Sources Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss Eli Lilly, "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" (July 23, 2026) TRIUMPH-2 (20.8% at 12 mg, A1C up to -1.6%) and TRIUMPH-3 (22.6% at 12 mg) topline, plus the stated plan to submit a BLA to the FDA in Q1 2027 ClinicalTrials.gov NCT05929066 (TRIUMPH-1) Phase 3, status Completed, primary completion April 6, 2026 Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) confirmed regulatory submission planned for 2026 Eli Lilly press releases and investor communications ClinicalTrials.gov (TRIUMPH program trial registrations) Jastreboff AM, et al
